Lithuania has emerged as a global leader in biotechnology, with a sector that has grown over 170% in recent years and a national commitment to reach 5% of the country’s GDP by 2030. This thriving ecosystem provides the ideal, high-innovation landscape to accelerate your molecule from concept to commercial reality.
Our facilities in Vilnius, dedicated to protein-based biologics, provide a seamless, vertically integrated pathway from cell line development through cGMP manufacturing of drug substance and drug product. We offer the rare flexibility of both microbial and mammalian expression platforms, featuring six independent mammalian production lines and three microbial lines designed for stable manufacturing. Every project is underpinned by rigorous quality systems, supported by meticulous documentation to accelerate your molecule’s journey to the clinic.
Number of R&D laboratories
Biologics facility size (m²)
Mammalian bioreactors (single-use)
Microbial fermenters
Drug Substance and Drug Product
Vials, Pre-Filled Syringes, Lyophilization
Our EU and US sites operate as one, same capabilities, same standards, full regulatory flexibility.
